Christelle de la Fouchardiere, MD, on Pancreatic Ductal Adenocarcinoma: Phase III Trial Results With Gemcitabine Plus Paclitaxel
ESMO Congress 2022
Christelle de la Fouchardiere, MD, of France’s Centre Léon Bérard, discusses phase III findings from the PRODIGE 65–UCGI 36–GEMPAX UNICANCER study, which evaluated whether the combination of gemcitabine and paclitaxel improves overall survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma after FOLFIRINOX failure or intolerance (Abstract LBA60).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The GEMPAX study is a phase III randomized trial comparing in patients with metastatic pancreatic ductal adenocarcinoma second-line therapy with gemcitabine and paclitaxel versus gemcitabine alone. The primary endpoint of this study was overhaul survival. Patients included were having metastatic pancreatic ductal adenocarcinoma, they were having experienced disease progression of failure after FOLFIRINOX, and maintaining a good ECOG performance status. They were randomized with a 2:1 ratio between GEMPAX, the weekly combination of gemcitabine and paclitaxel, 3 weeks over 4 versus gemcitabine alone. They stopped treatment at disease progression or toxicity. There were four stratification factors, ECOG PS, CA19-9 at baseline, first-line PFS, and neutrophil to lymphocyte ratio.
The main results of this study is that we didn't observe any significant benefit in overall survival with the addition of paclitaxel to gemcitabine versus gemcitabine alone in this setting. But this is the first prospective phase III trial evaluating second-line therapy after FOLFIRINOX and we observe a good improvement of progression-free survival, a significant one, and also a significant increase in overall response rate, which is highly clinically relevant in this poor prognosis disease. Furthermore, we observed more treatment discontinuation in the GEMPAX arm and also imbalance in third-line therapies that could explain the absence of overall survival benefit.
Then, we think that gemcitabine plus paclitaxel may be the standard second-line therapy after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma patients. A substantial proportion of patients in this study received third-line therapies, reflecting the eye medical need, and also the requiring further clinical trials for this pathology.
Related Videos
The ASCO Post Staff
Neil D. Gross, MD, of The University of Texas MD Anderson Cancer Center, discusses data from a phase II study, which showed that neoadjuvant cemiplimab-rwlc in patients with stage II–IV (M0) resectable cutaneous squamous cell carcinoma is active and may enable function-preserving surgery in some cases (Abstract 789O).
The ASCO Post Staff
Antonio Marra, MD, of Memorial Sloan Kettering Cancer Center, discusses a mutational signature analysis that reveals patterns of genomic instability linked to resistance to endocrine therapy with or without CDK4/6 inhibition in patients with estrogen receptor–positive/HER2-negative metastatic breast cancer (Abstract 210O).
The ASCO Post Staff
Charles Swanton, PhD, of The Francis Crick Institute, discusses a newly discovered mechanism of action for air pollution–induced non–small cell lung cancer in which particles linked to climate change appear to promote cancerous changes. The finding might pave the way for new potential approaches to lung cancer prevention and treatment (Abstract LBA1).
The ASCO Post Staff
Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the CheckMate 914 trial, which explored the efficacy of adjuvant nivolumab plus ipilimumab vs placebo in the treatment of patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (Abstract LBA4).
The ASCO Post Staff
John B.A.G. Haanen, MD, PhD, of The Netherlands Cancer Institute, discusses recent phase III findings, which show that tumor-infiltrating lymphocytes (TILs) improve progression-free survival compared with ipilimumab by 50% in patients with advanced melanoma after not responding to anti–PD-1 treatment. Around 50% of TIL-treated patients had a response, and 20% had a complete response (Abstract LBA3).
